Harbor

Executive Summary

Harbor is a private biotechnology company headquartered in Boston, Massachusetts, focused on developing novel immunotherapies and targeted treatments for cancer, autoimmune disorders, and infectious diseases. Founded in 2016, the company employs 50-200 people and has advanced to Phase 2 clinical trials. Harbor's approach centers on modulating the immune system to achieve durable responses, leveraging both biologics and small molecules. Despite being in a competitive landscape, Harbor's diversified pipeline across multiple therapeutic areas—oncology, immunology, and infectious disease—positions it to address significant unmet medical needs. The company is currently privately held with no disclosed funding or valuation, indicating it may still be in early revenue generation or relying on private investors. Key upcoming milestones include potential Phase 2 data readouts for its lead oncology candidate, which could de-risk the platform and attract partnership interest.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead oncology candidate50% success
• Q4 2026Strategic partnership or licensing deal for autoimmune program40% success
• Q1 2027Series B or C financing round announcement60% success